Incyte (INCY) Profit Margin History
Historical gross, operating and net quarterly profit margin for Incyte (INCY) over the last 10 years. The current net profit margin for Incyte as of January 19, 2018 is -10.9%.
|Medical||Medical - Biomedical and Genetics||$19.660B||$1.106B|
|Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer.|